To the Editors:
We agree with Chao and Han that uncertainty exists about the cytokeratins recognized by the CAM5.2 antibody in immunohistochemistry.1,2 It has become clear from immunoblot experiments that CAM5.2 is specific for cytokeratin 8 and to a lesser extent for the closely related cytokeratin 7, but not for cytokeratin 18.3,4 Nevertheless, CAM5.2 is generally accepted to be suitable for detection of metastatic breast cancer in (sentinel) lymph nodes because almost all breast carcinomas also strongly express cytokeratin 7.
References
Koolen BB, Valdés Olmos RA, Wesseling J, et al. Early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II–III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20:2227–35.
Chao WR, Han CP. Anti-cytokeratin CAM5.2 recognized CK8 mainly, but not CK18: comment on “early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II–III breast cancer: implications for surgical management of the axilla.” Ann Surg Oncol. (in press).
Makin CA, Bobrow LG, Bodmer WF. Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol. 1984;37:975–83.
BD Biosciences. Anti-cytokeratin (CAM 5.2). Specification sheet. http://www.bdbiosciences.com/external_files/is/doc/tds/Datasheets_RUO/live/web_enabled/23-1336-09-347653-347204-349205-DS-ruo.pdf.
Conflict of interest
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koolen, B.B., Wesseling, J. Reply to “Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on ‘Early Assessment of Axillary Response with 18F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Ann Surg Oncol. 2013;20(7):2227–35’”. Ann Surg Oncol 21, 700 (2014). https://doi.org/10.1245/s10434-013-3273-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-013-3273-2